Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

33.17 +1.08 (+3.37%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,443,507
Open 32.35
Bid (Size) 33.16 (10)
Ask (Size) 33.25 (1)
Prev. Close 32.09
Today's Range 32.30 - 33.23
52wk Range 31.77 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.70%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna's Shares Could Take Off if These 2 Things Happen
Moderna stock soared early in the pandemic. 
Via The Motley Fool
Why Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle. 
Via The Motley Fool
Exposures COVID-19

Performance

YTD
-35.29%
-35.29%
1 Month
-6.25%
-6.25%
3 Month
-9.50%
-9.50%
6 Month
-19.78%
-19.78%
1 Year
-24.20%
-24.20%

More News

Read More
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
Where Will Pfizer Be in 5 Years?
Via The Motley Fool
Is NYSE:PFE suited for dividend investing?
Via Chartmill
5 Stocks That Have Massive Upside According to Analysts
Via MarketBeat
Why the dividend investor may take a look at NYSE:PFE.
Via Chartmill
After Achieving 100% Cancer Remission Rates In Preclinical Studies, Starpax Magnetodrones Head For Human Trials
Via News Direct
Topics Death
Exposures Death
Smart Picks: 7 Blue-Chips Trading Below True Value
Via InvestorPlace
Kevin Dodelande's iMi launches into early cancer detection
Via IssueWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
Via InvestorPlace
Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold
Via Benzinga
Why Pfizer Stock Hit A New 52-Week Low Today
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Via Benzinga
Why Ginkgo Bioworks Stock Is Surging Higher Today
Via The Motley Fool
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
Via Benzinga
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
Via Benzinga
These 2 Stocks Are Getting Smart Investors' Attention Wednesday
Via The Motley Fool
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pfizer Is Sending Ginkgo Bioworks (DNA) Stock Higher: Here's Why
Via Benzinga
DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer
Via InvestorPlace
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Uncertainty Looms Over Pfizer's Oral COVID-19 Antiviral Pill - Doubts Over Commercial Approval
Via Benzinga
Exposures COVID-19
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Via TheNewswire.com
2 Magnificent Growth Stocks to Buy On the Dip
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.